Investors consider value of Cubist's Trius, Optimer buys
This article was originally published in Scrip
The market has had a full 24 hours to digest the news that Cubist Pharmaceuticals will buy two antibiotic developers to expand its portfolio of hospital-administered medicines, and investors weighed in with pretty clear opinions about the transactions, which will return up to $1.62 billion to Trius Therapeutics and Optimer Pharmaceuticals shareholders.
You may also be interested in...
Private Company Edition: The average exit from biopharma investments rose from $356.8m in 2019 to $520.6m in 2020, explaining the staggering $12bn invested in the industry during the first half of this year versus $17bn for all of last year. In recent VC deals, VelosBio’s $137m series B was the largest.
Neutralizing antibodies were seen in all 45 people injected across three dose levels in the first-in-human study. The middle dose of 100mcg will be tested in the company’s Phase III trial starting 27 July.
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.